Search
Ascentage Pharma-B (06855.HK) Showcases Multiple Research Breakthroughs at the 2025 European Hematology Association Annual Meeting
2 day ago /
Read about 0 minute
Author：小编
At the 2025 Annual Meeting of the European Hematology Association (EHA), Ascentage Pharma unveiled 13 significant research advancements for its pioneering drugs Orelabrutinib and the EED inhibitor APG-5918. Orelabrutinib, a novel third-generation TKI, showcased promising results in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Additionally, APG-5918 demonstrated robust anti-tumor activity in preclinical models of T-cell lymphoma, setting a strong foundation for future clinical development.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
